NCT01529619View on ClinicalTrials.gov

Efficacy, Safety and Tolerability of Rivastigmine Patch in Patients With Mild to Moderate Alzheimer's Disease Switched From Cholinesterase Inhibitors

PHASE4CompletedINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

March 31, 2012

Primary Completion Date

December 31, 2013

Study Completion Date

December 31, 2013

Conditions
Alzheimer's Disease
Interventions
DRUG

Rivastigmine transdermal patch

Trial Locations (11)

467-8602

Novartis Investigative Site, Nagoya

814-0180

Novartis Investigative Site, Fukuoka

728-0013

Novartis Investigative Site, Miyoshi

739-0696

Novartis Investigative Site, Ohtake

761-0793

Novartis Investigative Site, Kita-gun

247-8533

Novartis Investigative Site, Kamakura

216-8511

Novartis Investigative Site, Kawasaki

241-0811

Novartis Investigative Site, Yokohama

861-1116

Novartis Investigative Site, Kōshi

600-8558

Novartis Investigative Site, Kyoto

606-0851

Novartis Investigative Site, Kyoto

Sponsors
All Listed Sponsors
collaborator

Ono Pharmaceutical Co. Ltd

INDUSTRY

lead

Novartis Pharmaceuticals

INDUSTRY